BR112014006596A2 - nanopartícula que encapsula uma pluralidade de nanocarreadores, composição, uso de uma nanopartícula, kit, sistema de entrega, processo para obter uma nanopartícula, e, processo de nanoaspersão para obter as nanopartículas - Google Patents
nanopartícula que encapsula uma pluralidade de nanocarreadores, composição, uso de uma nanopartícula, kit, sistema de entrega, processo para obter uma nanopartícula, e, processo de nanoaspersão para obter as nanopartículasInfo
- Publication number
- BR112014006596A2 BR112014006596A2 BR112014006596A BR112014006596A BR112014006596A2 BR 112014006596 A2 BR112014006596 A2 BR 112014006596A2 BR 112014006596 A BR112014006596 A BR 112014006596A BR 112014006596 A BR112014006596 A BR 112014006596A BR 112014006596 A2 BR112014006596 A2 BR 112014006596A2
- Authority
- BR
- Brazil
- Prior art keywords
- nanoparticle
- obtaining
- nanocarriers
- nanoparticles
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
resumo nanopartícula que encapsula uma pluralidade de nanocarreadores, composição, uso de uma nanopartícula, kit, sistema de entrega, processo para obter uma nanopartícula, e, processo de nanoaspersão para obter as nanopartículas a presente invenção faz uso de uma metodologia única de encapsulação dupla para proteger e controlar a liberação de agentes ativos, seja hidrofóbico ou hidrofílico, a partir de nanopartículas estáveis de características opostas. a proteção do agente ativo foi alcançada ao carregar o agente a ser protegido em nanocarreadores, que foram subsequentemente encapsulados em nanopartículas submicrônicas. a formação de nanopartículas submicrônicas foi alcançada com sucesso pelo uso de técnicas de nanoaspersão inovadoras. 1/1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161537241P | 2011-09-21 | 2011-09-21 | |
PCT/IL2012/050382 WO2013042125A2 (en) | 2011-09-21 | 2012-09-20 | Nano delivery systems |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014006596A2 true BR112014006596A2 (pt) | 2017-03-28 |
Family
ID=47192058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014006596A BR112014006596A2 (pt) | 2011-09-21 | 2012-09-20 | nanopartícula que encapsula uma pluralidade de nanocarreadores, composição, uso de uma nanopartícula, kit, sistema de entrega, processo para obter uma nanopartícula, e, processo de nanoaspersão para obter as nanopartículas |
Country Status (9)
Country | Link |
---|---|
US (2) | US9421173B2 (pt) |
EP (1) | EP2758036A2 (pt) |
JP (1) | JP6214004B2 (pt) |
KR (1) | KR20140098739A (pt) |
CN (1) | CN104159572A (pt) |
BR (1) | BR112014006596A2 (pt) |
CA (1) | CA2849378A1 (pt) |
RU (1) | RU2014112958A (pt) |
WO (1) | WO2013042125A2 (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
NZ579107A (en) | 2007-02-19 | 2012-05-25 | Marinepolymer Tech Inc | Poly-beta-1-4-n-acetylglucosamine hemostatic compositions and therapeutic regimens |
CA2723114C (en) | 2008-05-16 | 2018-02-27 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
CA2735522C (en) | 2008-08-28 | 2017-04-18 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc |
CN103764265A (zh) | 2011-07-06 | 2014-04-30 | 哈佛学院院长等 | 多重乳剂和用于配制多重乳剂的技术 |
CA2849378A1 (en) * | 2011-09-21 | 2013-03-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nano delivery systems for sirna |
SG10201700459XA (en) | 2012-07-20 | 2017-02-27 | Taiga Biotechnologies Inc | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
CN104755108B (zh) * | 2012-10-25 | 2018-04-27 | 艾姆戈特株式会社 | 结合含有药物的纳米粒子的超声波造影剂及其制造方法 |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
AU2015208699B2 (en) * | 2014-01-27 | 2019-06-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Nanoencapsulation of hydrophilic active compounds |
WO2016007629A2 (en) * | 2014-07-08 | 2016-01-14 | University Of Maryland, Baltimore | Compositions and delivery methods for treating dental infections, inflammation, sensitivity, and for use in dental restorations |
US20160136179A1 (en) * | 2014-11-18 | 2016-05-19 | PixarBio Corporation | Compositions For Treating Acute, Post-Operative, Or Chronic Pain and Methods of Using the Same |
WO2016085740A1 (en) * | 2014-11-24 | 2016-06-02 | The Procter & Gamble Company | Compositions comprising encapsulated actives within droplets and other compartments |
CN104897597A (zh) * | 2015-05-29 | 2015-09-09 | 厦门成坤生物技术有限公司 | 核酸制剂的检测试剂及核酸制剂检测方法 |
CN114533898A (zh) | 2015-07-09 | 2022-05-27 | 加利福尼亚大学董事会 | 融合脂质体包被的多孔硅纳米颗粒 |
KR101708683B1 (ko) * | 2015-09-23 | 2017-02-21 | 서강대학교 산학협력단 | 서방형 약물 방출 콘텍트렌즈 |
CN109195590A (zh) * | 2015-11-03 | 2019-01-11 | 纳米珀特伊根公司 | 聚合纳米颗粒 |
WO2017126987A1 (ru) * | 2016-01-18 | 2017-07-27 | Анатолий Викторович ЗАЗУЛЯ | Эритроциты для направленного транспорта лекарственного средства |
WO2017181115A1 (en) * | 2016-04-14 | 2017-10-19 | Spinnaker Biosciences, Inc. | Porous silicon materials comprising a metal silicate for delivery of therapeutic agents |
WO2018023005A1 (en) * | 2016-07-28 | 2018-02-01 | Waters Technologies Corporation | Encapsulated pre-analytic workflows for flow-through devices, liquid chromatography and mass spectrometric analysis |
IL281425B (en) | 2016-12-02 | 2022-07-01 | Taiga Biotechnologies Inc | Nanoparticle formulations |
CN108358995B (zh) * | 2017-01-25 | 2021-07-06 | 四川大学 | CP-iRGD多肽、iDPP纳米粒、载药复合物及其制备方法和应用 |
AU2018287142B2 (en) * | 2017-06-21 | 2024-03-28 | Consejo Nacional De Investigaciones Científicas Y Técnicas | Albumin nanoparticles for the treatment of cancer and ocular diseases |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
CN108272768B (zh) * | 2017-10-20 | 2019-07-26 | 中山大学 | 负载治疗性蛋白的纳米粒及其微胶囊 |
ES2711669A1 (es) * | 2017-11-02 | 2019-05-06 | Univ Santiago Compostela | Sistemas de liberacion de farmacos de acido polisialico y metodos |
CN107875400B (zh) * | 2017-11-20 | 2020-10-30 | 南通大学 | 一种壳-核结构的siRNA仿病毒递送系统及应用 |
JP7092974B2 (ja) * | 2018-03-26 | 2022-06-29 | 株式会社リコー | 樹脂微粒子の製造方法、及び樹脂微粒子の製造装置 |
WO2019220441A1 (en) | 2018-05-15 | 2019-11-21 | Hadasit Medical Research Services And Development Ltd. | Compositions and methods for treating cancer resistant to an anti-cancer agent |
WO2019226612A1 (en) * | 2018-05-21 | 2019-11-28 | The United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating rsv-infections |
BR112021006821A2 (pt) * | 2018-10-12 | 2021-07-13 | Hovione Scientia Limited | método de tratamento de inflamação e patologias oftálmicas, dispersão sólida, formulação farmacêutica, método de matar ácaros e kit |
CN109549934B (zh) * | 2018-12-25 | 2021-03-09 | 上海交通大学 | 一种多糖基脂质纳米粒子的制备方法 |
RU2733715C2 (ru) * | 2019-01-18 | 2020-10-06 | Акционерное Общество "Производственная Фармацевтическая Компания Обновление" | Фармацевтическая субстанция для формирования лекарственных препаратов на основе Грамицидина С и способ ее получения (варианты), фармацевтическая субстанция для формирования лекарственных препаратов пролонгированного действия на основе Грамицидина С и способ ее получения (варианты) |
CN110051650A (zh) * | 2019-04-29 | 2019-07-26 | 南京锐利施生物技术有限公司 | 用于玻璃体注射的贝伐单抗和地塞米松共载的纳米粒药物 |
CN110302369B (zh) * | 2019-06-28 | 2022-04-29 | 中国人民解放军陆军军医大学 | 以壳聚糖修饰PLGA的大肠杆菌Vo外膜蛋白纳米粒疫苗及其制备方法和应用 |
CN110448541B (zh) * | 2019-08-02 | 2021-10-01 | 中山大学 | 双功能化纳米粒、可溶性微针及其制备方法与应用 |
JP2023542211A (ja) | 2020-09-21 | 2023-10-05 | アスクレピオス バイオファーマシューティカル, インコーポレイテッド | 神経疾患を処置するための方法 |
WO2022154463A1 (ko) * | 2021-01-15 | 2022-07-21 | 랩인큐브 주식회사 | 금속유기 복합입자 및 금속유기 복합입자를 포함하는 조성물 |
CN114848831A (zh) * | 2022-03-16 | 2022-08-05 | 成都威斯津生物医药科技有限公司 | 包裹型纳米制剂及其载体的制备方法和应用 |
CN115317448B (zh) * | 2022-09-05 | 2024-03-15 | 贵州医科大学 | 一种用于负载挥发油类药物的纳米乳剂及其制备方法 |
CN116603117B (zh) * | 2023-07-13 | 2023-10-13 | 四川大学华西医院 | 一种具有药物释放性能的超疏水药物结构涂层及其制法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003062372A2 (en) * | 2001-10-02 | 2003-07-31 | The Regents Of The University Of California | Nanoparticle assembled hollow spheres |
WO2004048545A2 (en) * | 2002-11-26 | 2004-06-10 | University Of Massachusetts | DELIVERY OF siRNAs______________________________________________ |
US7723311B2 (en) * | 2003-06-18 | 2010-05-25 | Nanobiomagnetics, Inc. | Delivery of bioactive substances to target cells |
US20050147963A1 (en) * | 2003-12-29 | 2005-07-07 | Intel Corporation | Composite organic-inorganic nanoparticles and methods for use thereof |
JP2007029361A (ja) * | 2005-07-26 | 2007-02-08 | Aruze Corp | 遊技機 |
WO2007029361A1 (ja) | 2005-09-02 | 2007-03-15 | Takeda Pharmaceutical Company Limited | 短鎖デオキシリボ核酸又は短鎖リボ核酸含有徐放性マイクロスフェア及びその製造法 |
JP2007099631A (ja) | 2005-09-30 | 2007-04-19 | Hosokawa Funtai Gijutsu Kenkyusho:Kk | アニオン性薬物封入ナノ粒子の製造方法及びそれを用いた医薬製剤 |
ATE446087T1 (de) | 2006-01-23 | 2009-11-15 | Yissum Res Dev Co | Mikrokügelchen mit nanokapseln, die ein lipophiles arzneimittel enthalten |
JP5115951B2 (ja) * | 2006-03-17 | 2013-01-09 | 学校法人東京理科大学 | ナノコンポジット粒子 |
CA2729923A1 (en) * | 2007-07-06 | 2009-01-15 | Aarhus Universitet | Dehydrated chitosan nanoparticles |
US8557290B2 (en) * | 2008-03-14 | 2013-10-15 | Northwestern University | Multifunction nanoconjugates for imaging applications and targeted treatment |
US20090312402A1 (en) | 2008-05-20 | 2009-12-17 | Contag Christopher H | Encapsulated nanoparticles for drug delivery |
US8541568B2 (en) * | 2008-05-24 | 2013-09-24 | Hai Yan | Compositions and methods using siRNA molecules for treatment of gliomas |
EP2366386A4 (en) | 2008-10-28 | 2013-11-27 | Univ Santiago Compostela | NANOPARTICULAR SYSTEMS MADE OF ANIONIC POLYMERS |
JP5733551B2 (ja) * | 2010-03-02 | 2015-06-10 | 学校法人東京理科大学 | ナノコンポジット粒子およびその製造方法 |
US10500156B2 (en) * | 2010-03-24 | 2019-12-10 | Northeastern University | Multi-compartmental macrophage delivery |
CA2801535C (en) | 2010-06-04 | 2017-05-30 | Hough Ear Institute | Composition and method for inner ear sensory hair cell regeneration or replacement |
CA2849378A1 (en) * | 2011-09-21 | 2013-03-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nano delivery systems for sirna |
-
2012
- 2012-09-20 CA CA2849378A patent/CA2849378A1/en not_active Abandoned
- 2012-09-20 BR BR112014006596A patent/BR112014006596A2/pt not_active IP Right Cessation
- 2012-09-20 EP EP12787908.8A patent/EP2758036A2/en active Pending
- 2012-09-20 JP JP2014531376A patent/JP6214004B2/ja active Active
- 2012-09-20 US US14/345,154 patent/US9421173B2/en active Active
- 2012-09-20 CN CN201280057034.3A patent/CN104159572A/zh active Pending
- 2012-09-20 KR KR1020147009715A patent/KR20140098739A/ko not_active Application Discontinuation
- 2012-09-20 WO PCT/IL2012/050382 patent/WO2013042125A2/en active Application Filing
- 2012-09-20 RU RU2014112958/15A patent/RU2014112958A/ru not_active Application Discontinuation
-
2016
- 2016-06-14 US US15/181,944 patent/US20160317460A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20140098739A (ko) | 2014-08-08 |
EP2758036A2 (en) | 2014-07-30 |
US20150037427A1 (en) | 2015-02-05 |
JP2014527980A (ja) | 2014-10-23 |
US9421173B2 (en) | 2016-08-23 |
WO2013042125A2 (en) | 2013-03-28 |
US20160317460A1 (en) | 2016-11-03 |
JP6214004B2 (ja) | 2017-10-25 |
CN104159572A (zh) | 2014-11-19 |
RU2014112958A (ru) | 2015-10-27 |
CA2849378A1 (en) | 2013-03-28 |
WO2013042125A3 (en) | 2013-08-01 |
WO2013042125A8 (en) | 2013-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014006596A2 (pt) | nanopartícula que encapsula uma pluralidade de nanocarreadores, composição, uso de uma nanopartícula, kit, sistema de entrega, processo para obter uma nanopartícula, e, processo de nanoaspersão para obter as nanopartículas | |
BR112015005940A2 (pt) | processo para a preparação de nanopartículas terapêuticas | |
PE20080765A1 (es) | Formas de dosificacion farmaceutica | |
MX2015010083A (es) | Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos. | |
BR112016009643A2 (pt) | composição nanoparticulada, célula dendrítica artificial, método para estimular ou intensificar uma resposta imune e método para tratar câncer | |
BR112015018947A2 (pt) | estrutura de memória tridimensional | |
BR112014002757A2 (pt) | encapsulados | |
EA201400972A1 (ru) | Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения | |
CY1124380T1 (el) | Συστηματα διαβλεννογονιας και διαδερμικης χορηγησης | |
BR112017012363A2 (pt) | microcápsulas revestidas | |
WO2015184256A3 (en) | Biodegradable lipids for delivery of nucleic acids | |
BR112015012547A2 (pt) | composições de prostaciclina e métodos de sua utilização | |
CL2014003509A1 (es) | Composición veterinaria masticable blanda que comprende como agente activo un compuesto derivado de isoxazolina; y su uso para el tratamiento y/o prevención de una infestación y/o infección por parásitos en un animal (div. sol. n°2087-14). | |
CY1124917T1 (el) | Παρασκευη στερεων συμπλοκων κυκλοδεξtρινης για παραδοση οφθαλμικου δραστικου φαρμακευτικου συστατικου | |
PE20150997A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos para realizarlas y usarlas | |
JP2017517556A5 (pt) | ||
WO2015152693A3 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
GT201300166A (es) | Formas de dosis de liberacion controlada encerradas resistentes a manipulaciones indebidas | |
CR20120140A (es) | Composiciones de liberación controlada | |
BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
BR112012005969A2 (pt) | forma de dosagem sólida oral contendo nanopartículas e processo de formulação da mesma usando gelatina de peixe | |
CL2015001660A1 (es) | Composicion farmaceutica oral de accion prolongada (pap) que comprende un compuesto derivado de betulina en forma de microparticulas y encapsulado en un polimero, y un sistema tensoactivo que comprende un tensoactivo, un estabilizador y una sal amortiguadora; metodo para la prevencion y el tratamiento de una infeccion por vih. | |
EA201170610A1 (ru) | Композиции антиперспиранта | |
MX2018000637A (es) | Nanocápsula para la administración de un compuesto lipófilo y proceso de preparación de la misma. | |
WO2014106116A3 (en) | Therapeutic compositions comprising antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |